Does short-term (1-3 months) DAPT improve bleeding outcomes without increasing ischemic events compared to standard (12 months) DAPT in patients undergoing implantation of a new-generation DES?
Patients undergoing implantation of a new-generation drug-eluting stent (DES)
Short-term (1-3 months) dual antiplatelet therapy (DAPT)
Standard (12 months) dual antiplatelet therapy (DAPT)
All-cause mortality, cardiac death, myocardial infarction, stroke, and definite or probable stent thrombosishard clinical
In patients receiving new-generation DES, 1-3 months of DAPT reduces bleeding risk without compromising protection against stent thrombosis, MI, or death compared to standard 12-month DAPT.
In patients undergoing implantation of a new-generation of DES, short-term (1-3 months) DAPT exhibited no inferiority compared with standard (12 months) DAPT in terms of all-cause mortality, cardiac death, myocardial infarction, stroke, and definite or probable stent thrombosis compared with standard (12 months) DAPT. However, short-term DAPT appeared superior to standard DAPT in terms of major bleeding and all bleeding.
Building similarity graph...
Analyzing shared references across papers
Loading...
Penghui Xiong
Chunhua Zheng
Jianfeng Fan
Medicine
Nanchang University
First Affiliated Hospital of Nanchang University
S.P.E.C.I.E.S.
Building similarity graph...
Analyzing shared references across papers
Loading...
Xiong et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d572e975589c71d767e8ff — DOI: https://doi.org/10.1097/md.0000000000038071